Larimar Therapeutics, Inc. (LRMR) 8-K Current Report: February 27, 2026
Filed: February 27, 2026
Health Care
Pharmaceutical PreparationsLarimar Therapeutics, Inc. (LRMR) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
Larimar Therapeutics, Inc. 8-K Feb 27, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Larimar priced public offering of 20M shares at $5.00/share; underwriters exercised full 3M share overallotment on Feb 26, 2026
- • Total shares sold: 23M; net proceeds ~$107.6M after underwriting discounts and estimated expenses
- • Significant dilution event — 23M new shares issued; existing shareholders should assess impact on ownership percentage
- • J.P. Morgan and Guggenheim Securities acted as joint bookrunning managers; closing expected Feb 27, 2026
Other Larimar Therapeutics, Inc. 8-K Filings
Get deeper insights on Larimar Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.